Strategic Partnerships NeoVac is a clinical-stage biotech with a distinctive lipid nanoparticle platform for RNA vaccines and medicines. Sales opportunities include licensing the LNP technology to vaccine developers and pharma CDMOs, entering joint development agreements with biopharma to extend indications, and pursuing regional manufacturing partnerships to scale supply.

Growth Funding As a UK-based company with modest revenue and a lean team, NeoVac may attract strategic investments or grants. Potential sales angles include offering CRO and clinical trial support, regulatory and market-entry services, and collaboration packages to accelerate late-stage development and commercial readiness in Europe and North America.

Digital Security The current tech stack indicates a modern but vendor-spread web presence and development practices. Opportunities exist to provide cybersecurity hardening, data governance, and regulatory-compliant cloud infrastructure, plus ELN/LIMS integration and automation tools to improve R&D data integrity and audit readiness.

Data Platform The RNA delivery platform generates substantial data; there is demand for data management, analytics, and integration services. Propose selling cloud-ready data platforms, analytics dashboards, AI-driven insights, and API-based integrations to streamline partner collaborations and decision timelines.

Market Access NeoVac aims to broaden vaccine access, aligning with payer evidence, health economics, and regulatory strategy needs. Sales opportunities include regulatory affairs support, health economics and outcomes research, and commercialization planning to de-risk submissions and support reimbursement and adoption.